Yongxia Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yongxia Yang has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Hailong Shu
Guangdong Pharmaceutical University
3 shared publicationsWanting Chen
College of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China
3 shared publicationsMan Xu
College of Basic Medicine, Guangdong Pharmaceutical University, Guangzhou, China
2 shared publicationsRuihui Yang
Department of Cell Biology and Medical Genetics, School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, Guangdong, 510006, PR China
2 shared publicationsWeiping Li
The First Affiliated Hospital of Guangdong Pharmaceutical University
2 shared publicationsWeixiao Ke
Guangdong Pharmaceutical University
2 shared publications
Latest Publications
- 23 October 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 254 (Pt 4) , 118570
ZYX knockdown alleviates chemotherapy resistance in epithelial ovarian cancer
- 23 October 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 254 (Pt 4) , 118570
ZYX knockdown alleviates chemotherapy resistance in epithelial ovarian cancer
- 7 August 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 66 (16) , 10339-10355
MVGCL: Noise-Robust Multi-Source Similarity Fusion and Type-Aware Dual-Pathway Learning for Drug Repositioning
Drug repositioning can accelerate therapeutic discovery, but computational drug-disease association prediction remains constrained by noisy multisource similarities, heterogeneous biomedical semantics, and sparse supervision. We present MVGCL, a type-aware dual-pathway framework that combines noise-robust multisource similarity fusion with heterogeneous biological network representation learning and aligns the two pathways through a distribution-aware hierarchical contrastive strategy to improve representation consistency under sparse and noisy supervision. Under 10-fold cross-validation protocols consistent with prior work, MVGCL achieves the highest AUC and AUPR on all three benchmark data sets, reaching 0.9538/0.9511 on B-data set, 0.9871/0.9890 on C-data set, and 0.9818/0.9836 on F-data set, with consistent performance across varying negative sampling ratios and entity-wise split settings. Under a leakage-controlled protocol in which GIP kernels were recomputed exclusively from the training DDAs within each fold, MVGCL retained the highest AUC and AUPR among the compared GIP-based models, with AUC values of 0.9029, 0.9422, and 0.9145 on B-data set, C-data set, and F-data set, respectively. Case analyses on Alzheimer’s disease and Parkinson’s disease further show that MVGCL ranks literature-supported drugs highly and prioritizes biologically plausible candidates for follow-up investigation, supporting its utility for evidence-aware drug repositioning.
- 7 August 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 66 (16) , 10339-10355
MVGCL: Noise-Robust Multi-Source Similarity Fusion and Type-Aware Dual-Pathway Learning for Drug Repositioning
Drug repositioning can accelerate therapeutic discovery, but computational drug-disease association prediction remains constrained by noisy multisource similarities, heterogeneous biomedical semantics, and sparse supervision. We present MVGCL, a type-aware dual-pathway framework that combines noise-robust multisource similarity fusion with heterogeneous biological network representation learning and aligns the two pathways through a distribution-aware hierarchical contrastive strategy to improve representation consistency under sparse and noisy supervision. Under 10-fold cross-validation protocols consistent with prior work, MVGCL achieves the highest AUC and AUPR on all three benchmark data sets, reaching 0.9538/0.9511 on B-data set, 0.9871/0.9890 on C-data set, and 0.9818/0.9836 on F-data set, with consistent performance across varying negative sampling ratios and entity-wise split settings. Under a leakage-controlled protocol in which GIP kernels were recomputed exclusively from the training DDAs within each fold, MVGCL retained the highest AUC and AUPR among the compared GIP-based models, with AUC values of 0.9029, 0.9422, and 0.9145 on B-data set, C-data set, and F-data set, respectively. Case analyses on Alzheimer’s disease and Parkinson’s disease further show that MVGCL ranks literature-supported drugs highly and prioritizes biologically plausible candidates for follow-up investigation, supporting its utility for evidence-aware drug repositioning.
- Open Access
- 26 July 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-23
Association between taurine transporter SLC6A6 and breast cancer development and prognosis: a Mendelian randomization analysis
Background Breast cancer is the most common malignancy among women worldwide, with early screening and diagnosis being crucial for improving patient prognosis. Taurine, as an important metabolite, shows significant changes during breast cancer development, while the taurine transporter SLC6A6 may play a key role in breast cancer progression. Methods This study systematically investigated the relationship between taurine level changes and breast cancer development through cell experiments, animal models, and clinical sample analysis. 1H NMR and HPLC techniques were used to measure taurine levels in different breast cancer cell lines, MMTV-PyMT transgenic mouse models, and clinical patient serum. Molecular docking, functional analysis, and immune infiltration analysis were employed to explore the mechanism of SLC6A6. Mendelian randomization (MR) analysis was used to evaluate the causal relationship between immune cell subsets and breast cancer risk. Results Intracellular taurine levels were elevated, while extracellular taurine levels decreased in breast cancer cells, correlating with malignancy degree. Serum taurine levels in MMTV-PyMT mice and clinical patients decreased continuously with disease progression, with significant changes detectable at the carcinoma in situ stage. Serum taurine demonstrated good diagnostic value as an early breast cancer marker, with ROC analysis showing an AUC of 0.939, sensitivity of 0.900, and specificity of 1.000 in distinguishing benign tumors from carcinoma in situ. SLC6A6 was highly expressed in breast cancer tissues and significantly associated with poor patient prognosis. Mendelian randomization analysis revealed potential causal relationships between specific immune cell subsets (such as naive B cells, TCRgd cells) and breast cancer risk, while CD14+CD16− monocytes showed a protective effect. Single-cell sequencing analysis indicated that SLC6A6 is primarily enriched in endothelial cells and fibroblasts within tumor tissues. Conclusion Taurine metabolic reprogramming can serve as a potential marker for early breast cancer diagnosis. SLC6A6 participates in breast cancer progression by regulating taurine levels and influencing immune infiltration, representing an independent predictor of breast cancer prognosis and a potential therapeutic target.
- 26 July 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-23
Open AccessAssociation between taurine transporter SLC6A6 and breast cancer development and prognosis: a Mendelian randomization analysis
Background Breast cancer is the most common malignancy among women worldwide, with early screening and diagnosis being crucial for improving patient prognosis. Taurine, as an important metabolite, shows significant changes during breast cancer development, while the taurine transporter SLC6A6 may play a key role in breast cancer progression. Methods This study systematically investigated the relationship between taurine level changes and breast cancer development through cell experiments, animal models, and clinical sample analysis. 1H NMR and HPLC techniques were used to measure taurine levels in different breast cancer cell lines, MMTV-PyMT transgenic mouse models, and clinical patient serum. Molecular docking, functional analysis, and immune infiltration analysis were employed to explore the mechanism of SLC6A6. Mendelian randomization (MR) analysis was used to evaluate the causal relationship between immune cell subsets and breast cancer risk. Results Intracellular taurine levels were elevated, while extracellular taurine levels decreased in breast cancer cells, correlating with malignancy degree. Serum taurine levels in MMTV-PyMT mice and clinical patients decreased continuously with disease progression, with significant changes detectable at the carcinoma in situ stage. Serum taurine demonstrated good diagnostic value as an early breast cancer marker, with ROC analysis showing an AUC of 0.939, sensitivity of 0.900, and specificity of 1.000 in distinguishing benign tumors from carcinoma in situ. SLC6A6 was highly expressed in breast cancer tissues and significantly associated with poor patient prognosis. Mendelian randomization analysis revealed potential causal relationships between specific immune cell subsets (such as naive B cells, TCRgd cells) and breast cancer risk, while CD14+CD16− monocytes showed a protective effect. Single-cell sequencing analysis indicated that SLC6A6 is primarily enriched in endothelial cells and fibroblasts within tumor tissues. Conclusion Taurine metabolic reprogramming can serve as a potential marker for early breast cancer diagnosis. SLC6A6 participates in breast cancer progression by regulating taurine levels and influencing immune infiltration, representing an independent predictor of breast cancer prognosis and a potential therapeutic target.
- Open Access
- 11 July 2025
- Published by Scilight Press Pty Ltd in Health and Metabolism
- Vol. 2 (3)
Comparative Study on Metabolic Regulation of SAP Deletion in Normal Mice and Atherosclerotic Mice
SAP is a serum protein associated with an increased risk of cardiovascular events, and researches have shown a significant positive correlation between SAP and the pathogenesis of atherosclerosis. Our previous research found that SAP deficiency in ApoE-/- mice significantly reduced the formation of foam cells and the expression of pro-inflammatory factors, and caused significant metabolic changes. However, it is still unclear whether SAP deficiency has the same function and metabolic regulation effect on normal background mice. In this study, C57 and SAP-/- mice were used as models. Histopathological examinations were performed to evaluate the histomorphological changes of heart, liver, spleen, lung and kidney tissues in SAP-/- mice. The results showed that there were no significant histopathology changes in the main organs of SAP-/- mice, but there were significant differences in the serum metabolic profiles between C57 and SAP-/- mice. It was found that the deficiency of SAP in both C57 and ApoE-/- mice lead to an upregulation of choline, but the regulatory trends on LDL/VLDL were different. Acetate and pyruvate were regulated by SAP deficiency in ApoE-/- mice, but not in C57 mice. In addition, the deletion of SAP also caused significant changes in formate, tyrosine, glycine, glucose, TMAO, taurine, citrate, succinate, and histidine in C57 context, which were not found in the atherosclerosis background. In summary, this study indicates that the metabolic regulation of the SAP gene is not only related to the gene itself, but also related to the physiological or pathological state of the organism.
- 11 July 2025
- Published by Scilight Press Pty Ltd in Health and Metabolism
- Vol. 2 (3)
Open AccessComparative Study on Metabolic Regulation of SAP Deletion in Normal Mice and Atherosclerotic Mice
SAP is a serum protein associated with an increased risk of cardiovascular events, and researches have shown a significant positive correlation between SAP and the pathogenesis of atherosclerosis. Our previous research found that SAP deficiency in ApoE-/- mice significantly reduced the formation of foam cells and the expression of pro-inflammatory factors, and caused significant metabolic changes. However, it is still unclear whether SAP deficiency has the same function and metabolic regulation effect on normal background mice. In this study, C57 and SAP-/- mice were used as models. Histopathological examinations were performed to evaluate the histomorphological changes of heart, liver, spleen, lung and kidney tissues in SAP-/- mice. The results showed that there were no significant histopathology changes in the main organs of SAP-/- mice, but there were significant differences in the serum metabolic profiles between C57 and SAP-/- mice. It was found that the deficiency of SAP in both C57 and ApoE-/- mice lead to an upregulation of choline, but the regulatory trends on LDL/VLDL were different. Acetate and pyruvate were regulated by SAP deficiency in ApoE-/- mice, but not in C57 mice. In addition, the deletion of SAP also caused significant changes in formate, tyrosine, glycine, glucose, TMAO, taurine, citrate, succinate, and histidine in C57 context, which were not found in the atherosclerosis background. In summary, this study indicates that the metabolic regulation of the SAP gene is not only related to the gene itself, but also related to the physiological or pathological state of the organism.
- Open Access
- 1 November 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (11) , 5815-5829
Determining new disulfidptosis-associated lncRNA signatures pertinent to breast cancer prognosis and immunological microenvironment
Background: Disulfidptosis is a novel form of cell death triggered by disulfide stress that may have important implications for breast cancer (BC) pathogenesis. Nevertheless, studies identifying disulfidptosis-associated long non-coding RNAs (lncRNAs) in BC have not been reported. This study aimed to investigate the prognostic potential of disulfidptosis-related lncRNAs in BC. Methods: RNA-sequencing data and clinical information of BC patients were obtained from The Cancer Genome Atlas (TCGA) database. The lncRNAs associated with disulfidptosis were identified through co-expression analysis. Subsequently, a risk signature consisting of 10 lncRNAs was constructed using univariate Cox and least absolute shrinkage and selection operator (LASSO) analyses, and its predictive power was validated. Results: The risk signature was found to be an independent prognostic factor for BC patients. Notably, the two subgroups defined by the risk signature exhibited different mutant gene profiles, and risk scores were significantly correlated with tumor mutation burden (TMB). Additionally, single-sample gene set enrichment analysis (ssGSEA) and immune checkpoint analyses indicated that the predicted trait was significantly associated with the immune status of BC patients. Furthermore, 55 potential anticancer drugs were identified that were associated with the signature. Conclusions: In this study, we successfully developed a prognostic model based on disulfidptosis-related lncRNAs, which enhances the accuracy of predicting the prognosis of BC patients. This model also offers a potential target and theoretical foundation for BC treatment, laying a robust groundwork for future research on the functional roles of disulfidptosis-associated lncRNAs in BC.
- 1 November 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (11) , 5815-5829
Open AccessDetermining new disulfidptosis-associated lncRNA signatures pertinent to breast cancer prognosis and immunological microenvironment
Background: Disulfidptosis is a novel form of cell death triggered by disulfide stress that may have important implications for breast cancer (BC) pathogenesis. Nevertheless, studies identifying disulfidptosis-associated long non-coding RNAs (lncRNAs) in BC have not been reported. This study aimed to investigate the prognostic potential of disulfidptosis-related lncRNAs in BC. Methods: RNA-sequencing data and clinical information of BC patients were obtained from The Cancer Genome Atlas (TCGA) database. The lncRNAs associated with disulfidptosis were identified through co-expression analysis. Subsequently, a risk signature consisting of 10 lncRNAs was constructed using univariate Cox and least absolute shrinkage and selection operator (LASSO) analyses, and its predictive power was validated. Results: The risk signature was found to be an independent prognostic factor for BC patients. Notably, the two subgroups defined by the risk signature exhibited different mutant gene profiles, and risk scores were significantly correlated with tumor mutation burden (TMB). Additionally, single-sample gene set enrichment analysis (ssGSEA) and immune checkpoint analyses indicated that the predicted trait was significantly associated with the immune status of BC patients. Furthermore, 55 potential anticancer drugs were identified that were associated with the signature. Conclusions: In this study, we successfully developed a prognostic model based on disulfidptosis-related lncRNAs, which enhances the accuracy of predicting the prognosis of BC patients. This model also offers a potential target and theoretical foundation for BC treatment, laying a robust groundwork for future research on the functional roles of disulfidptosis-associated lncRNAs in BC.
- Open Access
- 1 June 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (6) , 2721-2734
Screening of postoperative adjuvant chemotherapy-related serum metabolic markers in breast cancer patients based on 1H NMR metabonomics
Background: Breast cancer (BC) has the highest incidence rate among female malignant tumors. Adjuvant chemotherapy is commonly used to reduce micrometastasis in postoperative patients. However, monitoring the efficacy of chemotherapy in BC is a major challenge in clinical practice. In this study, 1H nuclear magnetic resonance (NMR) metabonomics was performed to explore the serum metabolic characteristics of BC patients before and after adjuvant chemotherapy. Methods: In this study, we collected serum samples from 51 healthy controls and 61 BC patients before and after chemotherapy for 1H NMR metabolomic analysis, and tested the performance of each metabolite and combination segment by the receiver operating characteristic (ROC) curves. Results: Nine metabolites, namely glutamine, citrate, creatine, glycerophosphatidylcholine/phosphatidylcholine, glycine, 1-methylhistidine, lactate, pyruvate and formate had significant changes in BC patients before chemotherapy compared with healthy controls. Lactate, pyruvate, 1-methylhistidine and formate were found to be inversely regulated by chemotherapy. ROC analysis showed that a combination of the four metabolites had good prediction for chemotherapy efficacy with area under the curve of 0.958, sensitivity of 98.36% and specificity of 91.30%. There was no significant correlation between chemotherapy-related metabolites and clinical indicators of cancer patients, indicating that they can be used to evaluate the chemotherapy efficacy of patients with different clinical indicators. Conclusions: Effectively, dynamic and non-invasive metabolic markers for the evaluation of the efficacy of chemotherapy were identified in this study.
- 1 June 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (6) , 2721-2734
Open AccessScreening of postoperative adjuvant chemotherapy-related serum metabolic markers in breast cancer patients based on 1H NMR metabonomics
Background: Breast cancer (BC) has the highest incidence rate among female malignant tumors. Adjuvant chemotherapy is commonly used to reduce micrometastasis in postoperative patients. However, monitoring the efficacy of chemotherapy in BC is a major challenge in clinical practice. In this study, 1H nuclear magnetic resonance (NMR) metabonomics was performed to explore the serum metabolic characteristics of BC patients before and after adjuvant chemotherapy. Methods: In this study, we collected serum samples from 51 healthy controls and 61 BC patients before and after chemotherapy for 1H NMR metabolomic analysis, and tested the performance of each metabolite and combination segment by the receiver operating characteristic (ROC) curves. Results: Nine metabolites, namely glutamine, citrate, creatine, glycerophosphatidylcholine/phosphatidylcholine, glycine, 1-methylhistidine, lactate, pyruvate and formate had significant changes in BC patients before chemotherapy compared with healthy controls. Lactate, pyruvate, 1-methylhistidine and formate were found to be inversely regulated by chemotherapy. ROC analysis showed that a combination of the four metabolites had good prediction for chemotherapy efficacy with area under the curve of 0.958, sensitivity of 98.36% and specificity of 91.30%. There was no significant correlation between chemotherapy-related metabolites and clinical indicators of cancer patients, indicating that they can be used to evaluate the chemotherapy efficacy of patients with different clinical indicators. Conclusions: Effectively, dynamic and non-invasive metabolic markers for the evaluation of the efficacy of chemotherapy were identified in this study.
- 17 April 2024
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 47 (9) , 369-377
Taurine Inhibits Lung Metastasis in Triple-Negative Breast Cancer by Modulating Macrophage Polarization Through PTEN-PI3K/Akt/mTOR Pathway
Summary: Taurine (Tau) has been found to inhibit triple-negative breast cancer (TNBC) invasion and metastasis. However, its effect on tumor-promoting macrophages and tumor suppressor macrophages in breast cancer progression remains unknown. In this study, we investigated the effects of Tau on macrophage polarization and its role in TNBC cell growth, invasion, and metastasis. We induced human THP-1 monocytes to differentiate into M2 macrophages through exogenous addition of interleukin-4. We used the TNBC cell lines MDA-MB-231 and BT-549 cultured in a conditioned medium from M2 macrophages to investigate the effect of Tau on tumor growth and invasion. We analyzed macrophage subset distribution, M1 and M2 macrophage-associated markers, and mRNA expression by quantitative polymerase chain reaction. We also detected the PTEN-PI3K/Akt/mTOR signaling pathway that mediates M1 macrophage to suppress tumor invasion using western blotting. Our results showed that Tau inhibits breast cancer metastasis to the lungs in vivo and cell invasion by altering the polarization of tumor-associated macrophage in vitro. In addition, Tau can up-regulate PTEN expression, suppress the PI3K-Akt signaling pathway, and promote the M1 polarization of macrophages, which ultimately inhibits the metastasis of TNBC cells. Our findings suggest that Tau inhibits the activation of the PI3K-Akt-mTOR signaling pathway by up-regulating PTEN, promotes the proportion of M1 macrophages in tumor-associated macrophage, and suppresses the invasion and metastasis of TNBC. This provides a potential therapeutic approach to influence cancer progression and metastasis.
- 17 April 2024
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 47 (9) , 369-377
Taurine Inhibits Lung Metastasis in Triple-Negative Breast Cancer by Modulating Macrophage Polarization Through PTEN-PI3K/Akt/mTOR Pathway
Summary: Taurine (Tau) has been found to inhibit triple-negative breast cancer (TNBC) invasion and metastasis. However, its effect on tumor-promoting macrophages and tumor suppressor macrophages in breast cancer progression remains unknown. In this study, we investigated the effects of Tau on macrophage polarization and its role in TNBC cell growth, invasion, and metastasis. We induced human THP-1 monocytes to differentiate into M2 macrophages through exogenous addition of interleukin-4. We used the TNBC cell lines MDA-MB-231 and BT-549 cultured in a conditioned medium from M2 macrophages to investigate the effect of Tau on tumor growth and invasion. We analyzed macrophage subset distribution, M1 and M2 macrophage-associated markers, and mRNA expression by quantitative polymerase chain reaction. We also detected the PTEN-PI3K/Akt/mTOR signaling pathway that mediates M1 macrophage to suppress tumor invasion using western blotting. Our results showed that Tau inhibits breast cancer metastasis to the lungs in vivo and cell invasion by altering the polarization of tumor-associated macrophage in vitro. In addition, Tau can up-regulate PTEN expression, suppress the PI3K-Akt signaling pathway, and promote the M1 polarization of macrophages, which ultimately inhibits the metastasis of TNBC cells. Our findings suggest that Tau inhibits the activation of the PI3K-Akt-mTOR signaling pathway by up-regulating PTEN, promotes the proportion of M1 macrophages in tumor-associated macrophage, and suppresses the invasion and metastasis of TNBC. This provides a potential therapeutic approach to influence cancer progression and metastasis.
- Open Access
- 16 December 2022
- Published by MDPI AG in Metabolites
- Vol. 12 (12) , 1278
1H-NMR-Based Metabonomics Study to Reveal the Progressive Metabolism Regulation of SAP Deficiency on ApoE−/− Mice
Atherosclerosis is the most common disease of the vascular system and the metabolic disorder is one of its important molecular mechanisms. SAP protein is found to be highly expressed in atherosclerotic blood vessels. Our previous study found that SAP deficiency can significantly inhibit the development of atherosclerosis. However, the regulatory effect of SAP deficiency on AS metabolism is unknown. Based on 1H-NMR metabonomics, this study investigated the serum metabolic changes in ApoE−/−;SAP−/− mice compared with ApoE−/− mice during the whole progression of atherosclerosis. The results showed that acetate, pyruvate, choline and VLDL + LDL were statistically regulated to the normal levels as in C57 mice by SAP deficiency in ApoE−/−;SAP−/− mice at 8 w (without obvious plaques). With the appearance and aggravation of atherosclerotic plaques (8 + 4 w and 8 + 8 w), the four metabolites of acetate, pyruvate, choline and VLDL + LDL were continuously regulated, which were denoted as the metabolic regulatory markers of SAP deficiency. We also found that the changes in these four metabolites had nothing to do with high-fat diet. Therefore, it was revealed that SAP deficiency regulated the metabolic disorders in ApoE−/− prior to the appearance of obvious atherosclerotic plaques, which is one of the important mechanisms leading to the inhibition of atherosclerosis, providing a new basis for the application of SAP in atherosclerosis.
- 16 December 2022
- Published by MDPI AG in Metabolites
- Vol. 12 (12) , 1278
Open Access1H-NMR-Based Metabonomics Study to Reveal the Progressive Metabolism Regulation of SAP Deficiency on ApoE−/− Mice
Atherosclerosis is the most common disease of the vascular system and the metabolic disorder is one of its important molecular mechanisms. SAP protein is found to be highly expressed in atherosclerotic blood vessels. Our previous study found that SAP deficiency can significantly inhibit the development of atherosclerosis. However, the regulatory effect of SAP deficiency on AS metabolism is unknown. Based on 1H-NMR metabonomics, this study investigated the serum metabolic changes in ApoE−/−;SAP−/− mice compared with ApoE−/− mice during the whole progression of atherosclerosis. The results showed that acetate, pyruvate, choline and VLDL + LDL were statistically regulated to the normal levels as in C57 mice by SAP deficiency in ApoE−/−;SAP−/− mice at 8 w (without obvious plaques). With the appearance and aggravation of atherosclerotic plaques (8 + 4 w and 8 + 8 w), the four metabolites of acetate, pyruvate, choline and VLDL + LDL were continuously regulated, which were denoted as the metabolic regulatory markers of SAP deficiency. We also found that the changes in these four metabolites had nothing to do with high-fat diet. Therefore, it was revealed that SAP deficiency regulated the metabolic disorders in ApoE−/− prior to the appearance of obvious atherosclerotic plaques, which is one of the important mechanisms leading to the inhibition of atherosclerosis, providing a new basis for the application of SAP in atherosclerosis.
- Open Access
- 13 June 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 894285
Methyl Gallate Suppresses the Migration, Invasion, and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells via the AMPK/NF-κB Signaling Pathway in vitro and in vivo
Methyl gallate (MG), a polyphenolic compound found in plants, is widely used in traditional Chinese medicine. MG is known to alleviate several cancer symptoms. However, most studies that have reported the antitumor effects of MG have done so at the cellular level, and the inhibitory effect and therapeutic mechanism of MG in hepatocellular carcinoma (HCC) have not been extensively explored in vivo. We aimed to understand the therapeutic mechanism of MG in HCC in vitro and in vivo. MTT and colony formation assays were used to determine the impact of MG on the proliferation of a human HCC cell line, BEL-7402; wound healing and transwell assays were used to quantify the migration and invasion of HCC cells. Western blotting was used to quantify the expression of the AMPK/NF-κB signaling pathway proteins. In vivo tumor growth was measured in a xenograft tumor nude mouse model treated with MG, and hematoxylin–eosin staining and immunohistochemistry (IHC) were used to visualize the histological changes in the tumor tissue. We found that MG showed anti-proliferative effects both in vitro and in vivo. MG downregulated the protein expression of AMPK, NF-κB, p-NF-κB, and vimentin and upregulated the expression of E-cadherin in a dose-dependent manner. Additionally, MG inhibited the migration and invasion of HCC cells by decreasing MMP9 and MMP2 expression and increasing TIMP-2 expression. These were consistent with the results of IHC in vivo. MG inhibited the proliferation, migration, and invasion of HCC cells. This effect potentially involves the regulation of the AMPK/NF-κB pathway, which in turn impacts epithelial-mesenchymal transition and MMP expression.
- 13 June 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 894285
Open AccessMethyl Gallate Suppresses the Migration, Invasion, and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells via the AMPK/NF-κB Signaling Pathway in vitro and in vivo
Methyl gallate (MG), a polyphenolic compound found in plants, is widely used in traditional Chinese medicine. MG is known to alleviate several cancer symptoms. However, most studies that have reported the antitumor effects of MG have done so at the cellular level, and the inhibitory effect and therapeutic mechanism of MG in hepatocellular carcinoma (HCC) have not been extensively explored in vivo. We aimed to understand the therapeutic mechanism of MG in HCC in vitro and in vivo. MTT and colony formation assays were used to determine the impact of MG on the proliferation of a human HCC cell line, BEL-7402; wound healing and transwell assays were used to quantify the migration and invasion of HCC cells. Western blotting was used to quantify the expression of the AMPK/NF-κB signaling pathway proteins. In vivo tumor growth was measured in a xenograft tumor nude mouse model treated with MG, and hematoxylin–eosin staining and immunohistochemistry (IHC) were used to visualize the histological changes in the tumor tissue. We found that MG showed anti-proliferative effects both in vitro and in vivo. MG downregulated the protein expression of AMPK, NF-κB, p-NF-κB, and vimentin and upregulated the expression of E-cadherin in a dose-dependent manner. Additionally, MG inhibited the migration and invasion of HCC cells by decreasing MMP9 and MMP2 expression and increasing TIMP-2 expression. These were consistent with the results of IHC in vivo. MG inhibited the proliferation, migration, and invasion of HCC cells. This effect potentially involves the regulation of the AMPK/NF-κB pathway, which in turn impacts epithelial-mesenchymal transition and MMP expression.